British HIV Association, BASHH and FSRH Guidelines for the Management of the Sexual and Reproductive Health of People Living With HIV Infection 2008

A. Fakoya; H. Lamba; N. Mackie; R. Nandwani; A. Brown; E.J. Bernard; C. Gilling-Smith; C. Lacey; L. Sherr; P. Claydon; S. Wallage; B. Gazzard


HIV Medicine. 2008;9(9):681-720. 

In This Article

7.0 References

  1. Health Protection Agency. Mapping the Issues: HIV and Other Sexually Transmitted Infections in the United Kingdom. London: Health Protection Agency, 2005.

  2. Health Protection Agency. Annual Report: A Complex Picture: HIV and Other Sexually Transmitted Infections in the United Kingdom. London: Health Protection Agency, 2006.

  3. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA Study: an observational study. Lancet 2003; 362: 22-29.

  4. Simms I, Fenton KA, Ashton M et al. The re-emergence of syphilis in the United Kingdom: the new epidemic phases. Sex Transm Dis 2005; 32: 220-226.

  5. Nicoll A, Hamers FF. Are trends in HIV, gonorrhoea, and syphilis worsening in western Europe? BMJ 2002; 324: 1324-1327.

  6. French P, Ison CA, Macdonald N. Lymphogranuloma venereum in the United Kingdom. Sex Transm Infect 2005; 81: 97-98.

  7. Fox KK, del Rio C, Holmes KK et al. Gonorrhea in the HIV era: a reversal in trends among men who have sex with men. Am J Public Health 2001; 91: 959-964.

  8. Health Protection Agency. National Study of HIV in Pregnancy and Childhood (NSHPC). London: Health Protection Agency, 2007.

  9. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087-1088.

  10. Hawkins D, Blott M, Clayden P et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med 2005; 6 (Suppl 2): 107-148.

  11. Nandwani R. 2006 United Kingdom national guideline on the sexual health of people with HIV: sexually transmitted infections. Int J STD AIDS 2006; 17: 594-606.

  12. Nandwani R, Fisher M. Clinical standards for the screening and management of acquired syphilis in HIV-positive adults. Int J STD AIDS 2006; 17: 588-593.

  13. Fisher M, Benn P, Evans B et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006; 17: 81-92.

  14. Quinn TC. Association of sexually transmitted diseases and infection with the human immunodeficiency virus: biological cofactors and markers of behavioural interventions. Int J STD AIDS 1996; 7 (Suppl 2): 17-24.

  15. Laga M. Interactions between STDs and HIV infection. STD Bull 1992; 13: 3-6.

  16. Pepin J, Quigley M, Todd J et al. Association between HIV-2 infection and genital ulcer diseases among male sexually transmitted disease patients in the Gambia. AIDS 1992; 6: 489-493.

  17. Laga M, Manoka A, Kivuvu M et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7: 95-102.

  18. MedFASH. Recommended Standards for NHS HIV Services. London: MedFASH, 2003.

  19. Brook MG, Gilson R, Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). HIV Med 2005; 6 (Suppl 2): 84-95.

  20. Nelson M, Matthews G, Brook MG, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005; 6 (Suppl 2): 96-106.

  21. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 1998; 74: 399-404.

  22. Tedder RS, Gilson RJ, Briggs M et al. Hepatitis C virus: evidence for sexual transmission. BMJ 1991; 302: 1299-1302.

  23. Bernard EJ. Sexual transmission of hepatitis C. Available at:

  24. Donaldson L. Letter from Sir Liam Donaldson to all chief executives of primary care trusts and strategic health authorities in England: PEP access in the UK. Available at:

  25. Lyerly AD, Anderson J. Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics. Fertil Steril 2001; 75: 843-858.

  26. Englert Y, Van Vooren JP, Place I, Liesnard C, Laruelle C, Delbaere A. ART in HIV-infected couples: has the time come for a change of attitude? Hum Reprod 2001; 16: 1309-1315.

  27. Minkoff H, Santoro N. Ethical considerations in the treatment of infertility in women with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1748-1750.

  28. Shenfield F, Pennings G, Cohen J, Devroey P, Tarlatzis B, Sureau C. Taskforce 8: ethics of medically assisted fertility treatment for HIV-positive men and women. Hum Reprod 2004; 19: 2454-2456.

  29. Frodsham LC, Boag F, Barton S, Gilling-Smith C. Human immunodeficiency virus infection and fertility care in the United Kingdom: demand and supply. Fertil Steril 2006; 85: 285-289.

  30. Gray RH, Li X, Wawer MJ et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission: Rakai, Uganda. AIDS 2003; 17: 1941-1951.

  31. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331: 341-346.

  32. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1 opportunities for preventing sexual HIV-1 transmission. Curr HIV Res 2003; 1: 69-86.

  33. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996; 10 (Suppl. A): 75-82.

  34. Cu-Uvin S, Snyder B, Harwell JI et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42: 584-587.

  35. Vettore MV, Schechter M, Melo MF, Boechat LJ, Barroso PF. Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. J Infect 2006; 52: 290-293.

  36. Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35: 55-60.

  37. Vernazza PL, Troiani L, Flepp MJ et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14: 117-121.

  38. Cu-Uvin S, Caliendo AM, Reinert S et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14: 415-421.

  39. Sadiq ST, Taylor S, Kaye S et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16: 219-225.

  40. Winter AJ, Taylor S, Workman J et al. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999; 75: 261-263.

  41. Cohen MS, Hoffman IF, Royce RA et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349: 1868-1873.

  42. Barreiro P, Castilla JA, Labarga P, Soriano V. Is natural conception a valid option for HIV-serodiscordant couples? Hum Reprod 2007; 22: 2353-2358.

  43. Vernazza P, Hirschel B, Bernassconi E, Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective antiretroviral therapy are sexually non-infectious. Bull Med Suisses 2008; 89: 5.

  44. Liuzzi G, Chirianni A, Clementi M et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996; 10: 51-56.

  45. Coombs RW, Speck CE, Hughes JP et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177: 320-330.

  46. Zhang H, Dornadula G, Beumont M et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339: 1803-1809.

  47. Gilling-Smith C, Nicopoullos JDM, Cox A, Almeida P, Wood R, Vourliotis M. Detectable HIV in semen from HIV-positive men on HAART with undetectable serum viral load. Human reproduction. European Society for Human Reproduction and Embryology (ESHRE) Annual Meeting. Barcelona, July 2008.

  48. Frodsham LCG, Cox AD, Almeida A, Rozis G, Gilling-Smith C. In vitro fertilisation in HIV-positive women: potential mother-to-embryo viral transmission risk. Hum Reprod 2004; 9: 138.

  49. Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-929.

  50. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40: 96-101.

  51. Melo M, Varella I, Nielsen K, Turella L, Santos B. Demographic characteristics, sexual transmission and CD4 progression among heterosexual HIV-serodiscordant couples followed in Porto Algegre, Brazil. 16th International AIDS Conference. Toronto, ON, Canada, August 2006 [Abstract TUPE0430].

  52. Barreiro P, del Romero J, Leal M et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 324-326.

  53. Vernazza P. HAART improves quality of life: should we care about the quality of spermatozoa? AIDS 2008; 22: 647-648.

  54. Semprini AE, Fiore S. HIV and reproduction. Curr Opin Obstet Gynecol 2004; 16: 257-262.

  55. Bagasra O, Farzadegan H, Seshamma T, Oakes JW, Saah A, Pomerantz RJ. Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS 1994; 8: 1669-1674.

  56. Vernazza PL, Gilliam BL, Dyer J et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11: 987-993.

  57. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1997; 176: 960-968.

  58. Kim LU, Johnson MR, Barton S et al. Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. AIDS 1999; 13: 645-651.

  59. Baccetti B, Benedetto A, Collodel G, di Caro A, Garbuglia AR, Piomboni P. The debate on the presence of HIV-1 in human gametes. J Reprod Immunol 1998; 41: 41-67.

  60. Gilling-Smith C, Almeida P. HIV, hepatitis B and hepatitis C and infertility: reducing risk. Hum Fertil (Cambridge) 2003; 6: 106-112.

  61. Marina S, Marina F, Alcolea R, Nadal J, Exposito R, Huguet J. Pregnancy following intracytoplasmic sperm injection from an HIV-1-seropositive man. Hum Reprod 1998; 13: 3247-3249.

  62. Marina S, Marina F, Alcolea R et al. Human immunodeficiency virus type 1-serodiscordant couples can bear healthy children after undergoing intrauterine insemination. Fertil Steril 1998; 70: 35-39.

  63. Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care - a review of current practice. BJOG 2006; 113: 869-878.

  64. Politch JA, Xu C, Tucker L, Anderson DJ. Separation of human immunodeficiency virus type 1 from motile sperm by the double tube gradient method vs. other methods. Fertil Steril 2004; 81: 440-447.

  65. Sauer MV. Sperm washing techniques address the fertility needs of HIV-seropositive men: a clinical review. Reprod Biomed Online 2005; 10: 135-140.

  66. Bujan L, Hollander L, Coudert M et al. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE Network. AIDS 2007; 21: 1909-1914.

  67. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.

  68. Sauer MV, Choi J. HIV seroconversion in a woman preparing for assisted reproduction: an inherent risk in caring for HIV-serodiscordant couples. Reprod Biomed Online 2006; 12: 375-377.

  69. Nicopoullos JD, Almeida PA, Ramsay JW, Gilling-Smith C. The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod 2004; 19: 2289-2297.

  70. Waters L, Gilling-Smith C, Boag F. HIV infection and subfertility. Int J STD AIDS 2007; 18: 1-6.

  71. Coll O, Fiore S, Floridia M et al. Pregnancy and HIV infection: a European consensus on management. AIDS 2002; 16 (Suppl. 2): 1-18.

  72. Brunham RC, Cheang M, McMaster J, Garnett G, Anderson R. Chlamydia trachomatis, infertility, and population growth in sub-Saharan Africa. Sex Transm Dis 1993; 20: 168-173.

  73. Brunham RC, Garnett GP, Swinton J, Anderson RM. Gonococcal infection and human fertility in sub-Saharan Africa. Proc Biol Sci 1991; 246: 173-177.

  74. Frodsham LC, Smith JR, Gilling-Smith C. Assessment of welfare of the child in HIV-positive couples. Hum Reprod 2004; 19: 2420-2423.

  75. Gilling-Smith C. Risking parenthood? Serious viral illness, parenting and welfare of the child. In: Shenfield F, Sureau C, eds. Contemporary Ethical Dilemmas in Assisted Reproduction. London: Informa Healthcare, 2006: 57-69.

  76. Gilling-Smith C, Emiliani S, Almeida P, Liesnard C, Englert Y. Laboratory safety during assisted reproduction in patients with blood-borne viruses. Hum Reprod 2005; 20: 1433-1438.

  77. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-544.

  78. Bancroft J, Carnes L, Janssen E, Goodrich D, Long JS. Erectile and ejaculatory problems in gay and heterosexual men. Arch Sex Behav 2005; 34: 285-297.

  79. Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS 2004; 15: 234-237.

  80. Bancroft J, Carnes L, Janssen E. Unprotected anal intercourse in HIV-positive and HIV-negative gay men: the relevance of sexual arousability, mood, sensation seeking, and erectile problems. Arch Sex Behav 2005; 34: 299-305.

  81. Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS 2004; 15: 732-736.

  82. Collazos J, Martinez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 322-326.

  83. Collazos J, Mayo J, Martinez E, Ibarra S. Association between sexual disturbances and sexual hormones with specific antiretroviral drugs. AIDS 2002; 16: 1294-1295.

  84. Schrooten W, Colebunders R, Youle M et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001; 15: 1019-1023.

  85. Asboe D, Catalan J, Mandalia S et al. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care 2007; 19: 955-965.

  86. Hijazi L, Nandwani R, Kell P. Medical management of sexual difficulties in HIV-positive individuals. Int J STD AIDS 2002; 13: 587-592.

  87. Wespes E, Amar E, Hatzichristou D et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806-815.

  88. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000; 321: 499-503.

  89. Goldmeier D, Lamba H. Sexual dysfunction in HIV-positive individuals. Int J STD AIDS 2003; 14: 63-64.

  90. Richardson D, Lamba H, Goldmeier D, Nalabanda A, Harris JR. Factors associated with sexual dysfunction in men with HIV infection. Int J STD AIDS 2006; 17: 764-767.

  91. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.

  92. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002; 53 (Suppl. 1): 37-43.

  93. Sekar V, Lefebvre E, DeMarez T. Pharmacokinetic interaction between TMC114, a new protease inhibitor, and sildenafil. 8th International Congress on Drug Therapy in HIV. Glasgow, UK, November 2006 [Abstract A-0369].

  94. Scholler-Gyure M, Debroye C, Vyncke C. Effect of TMC125 on sildenafil pharmacokinetics. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, April 2006 [Abstract 45].

  95. Sherr L, Bolding G, Maguire M, Elford J. Viagra use and sexual risk behaviour among gay men in London. AIDS 2000; 14: 2051-2053.

  96. Rosen RC, Catania JA, Ehrhardt AA et al. The Bolger Conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. J Sex Med 2006; 3: 960-975.

  97. Richardson D, Goldmeier D, Green J, Lamba H, Harris JR. Recommendations for the management of premature ejaculation: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS 2006; 17: 1-6.

  98. Richardson D, Goldmeier D. Recommendations for the management of retarded ejaculation: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS 2006; 17: 7-13.

  99. Collazos J, Ibarra S, Martinez E, Mayo J. Serum prolactin concentrations in patients infected with human immunodeficiency virus. HIV Clin Trials 2002; 3: 133-138.

  100. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS 2005; 19: 655-671.

  101. Crum-Cianflone NF, Bavaro M, Hale B et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 2007; 21: 9-19.

  102. Elford J, Bolding G, Davis M, Sherr L, Hart G. Barebacking among HIV-positive gay men in London. Sex Transm Dis 2007; 34: 93-98.

  103. Bell C, Richardson D, Wall M, Goldmeier D. HIV-associated female sexual dysfunction - clinical experience and literature review. Int J STD AIDS 2006; 17: 706-709.

  104. Florence E, Schrooten W, Dreezen C et al. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care 2004; 16: 550-557.

  105. Keegan A, Lambert S, Petrak J. Sex and relationships for HIV-positive women since HAART: a qualitative study. AIDS Patient Care STDS 2005; 19: 645-654.

  106. Meyer-Bahlburg HF, Nostlinger C, Exner TM et al. Sexual functioning in HIV + and HIV - injected drug-using women. J Sex Marital Ther 1993; 19: 56-68.

  107. Hankins C, Gendron S, Tran T, Lamping D, Lapointe N. Sexuality in Montreal women living with HIV. AIDS Care 1997; 9: 261-271.

  108. Wright TC Jr, Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84: 591-597.

  109. Smith JR, Kitchen VS, Botcherby M et al. Is HIV infection associated with an increase in the prevalence of cervical neoplasia? Br J Obstet Gynaecol 1993; 100: 149-153.

  110. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164: 593-599.

  111. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729-730.

  112. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.

  113. Maiman M, Fruchter RG, Guy L, Cuthill S, Levine P, Serur E. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993; 71: 402-406.

  114. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.

  115. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.

  116. Palefsky JM, Minkoff H, Kalish LA et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91: 226-236.

  117. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-1349.

  118. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998; 178: 982-986.

  119. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.

  120. Petry KU, Scheffel D, Bode U et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994; 57: 836-840.

  121. Maiman M, Fruchter RG, Serur E, Levine PA, Arrastia CD, Sedlis A. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993; 82: 170-174.

  122. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 1459-1464.

  123. Lillo FB, Ferrari D, Veglia F et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547-551.

  124. Minkoff H, Ahdieh L, Massad LS et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15: 2157-2164.

  125. Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA. Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS 2002; 16: 927-929.

  126. National Health Service. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme. NHSCSP Publication. Available at

  127. Office for National Statistics. Registrations of Cancer Diagnosed in 2003, England. Available at

  128. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.

  129. Koblin BA, Hessol NA, Zauber AG et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 1996; 144: 916-923.

  130. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247: 1988-1990.

  131. Daling JR, Weiss NS, Hislop TG et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317: 973-977.

  132. Bower M, Powles T, Newsom-Davis T et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37: 1563-1565.

  133. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000; 36: 754-758.

  134. Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004; 5: 149-157.

  135. Frisch M, Fenger C, van den Brule AJ et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59: 753-757.

  136. Daling JR, Madeleine MM, Johnson LG et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280.

  137. Marfing TE, Abel ME, Gallagher DM. Perianal Bowen's disease and associated malignancies. Results of a survey. Dis Colon Rectum 1987; 30: 782-785.

  138. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Perianal Bowen's disease and anal intraepithelial neoplasia: review of the literature. Dis Colon Rectum 1999; 42: 945-951.

  139. Chin-Hong PV, Vittinghoff E, Cranston RD et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE Study. J Infect Dis 2004; 190: 2070-2076.

  140. Fenger C, Nielsen VT. Intraepithelial neoplasia in the anal canal. The appearance and relation to genital neoplasia. Acta Pathol Microbiol Immunol Scand A 1986; 94: 343-349.

  141. Piketty C, Darragh TM, Da Costa M et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: 453-459.

  142. Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. Br J Surg 2005; 92: 277-290.

  143. Critchlow CW, Surawicz CM, Holmes KK et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995; 9: 1255-1262.

  144. Palefsky J. Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol 1995; 7: 437-441.

  145. Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen's disease). Br J Surg 1999; 86: 1063-1066.

  146. Papaconstantinou HT, Lee AJ, Simmang CL et al. Screening methods for high-grade dysplasia in patients with anal condyloma. J Surg Res 2005; 127: 8-13.

  147. Arain S, Walts AE, Thomas P, Bose S. The Anal Pap Smear: cytomorphology of squamous intraepithelial lesions. Cytojournal 2005; 2: 4.

  148. Carter PS, Sheffield JP, Shepherd N et al. Interobserver variation in the reporting of the histopathological grading of anal intraepithelial neoplasia. J Clin Pathol 1994; 47: 1032-1034.

  149. Negri G, Moretto G, Menia E et al. Immunocytochemistry of p16INK4a in liquid-based cervicovaginal specimens with modified Papanicolaou counterstaining. J Clin Pathol 2006; 59: 827-830.

  150. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 1127-1134.

  151. Fox PA, Seet JE, Stebbing J et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect 2005; 81: 142-146.

  152. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002; 45: 453-458.

  153. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005; 48: 1042-1054.

  154. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281: 1822-1829.

  155. Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 2004; 190: 1685-1691.

  156. Elford J, Bolding G, Sherr L, Hart G. High-risk sexual behaviour among London gay men: no longer increasing. AIDS 2005; 19: 2171-2174.

  157. Kamb ML, Fishbein M, Douglas JM Jr et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280: 1161-1167.

  158. Metcalf CA, Malotte CK, Douglas JM Jr et al. Efficacy of a booster counseling session 6 months after HIV testing and counseling: a randomized, controlled trial (RESPECT-2). Sex Transm Dis 2005; 32: 123-129.

  159. Sangani P, Rutherford G, Wilkinson D. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2004, CD001220.

  160. Hart GJ, Williamson LM, Flowers P. Good in parts: the Gay Men's Task Force in Glasgow - a response to Kelly. AIDS Care 2004; 16: 159-165.

  161. Department of Health. Guidelines for HIV Testing in Pregnancy. London: Department of Health, 2007.

  162. Postma MJ, Beck EJ, Hankins CA et al. Cost effectiveness of expanded antenatal HIV testing in London. AIDS 2000; 14: 2383-2389.

  163. Sherr L, Barry N. Fatherhood and HIV-positive heterosexual men. HIV Med 2004; 5: 258-263.

  164. Bergenstrom A, Sherr L. HIV testing and prevention issues for women attending termination assessment clinics. Br J Fam Plan 1999; 25: 3-8.

  165. Bergenstrom A, Sherr L, Okolo S. HIV testing and prevention: family planning clinic attenders in London. Sex Transm Infect 1999; 75: 130.

  166. Goldstein RB, Johnson MO, Rotheram-Borus MJ et al. Psychological distress, substance use, and adjustment among parents living with HIV. J Am Board Fam Pract 2005; 18: 363-373.

  167. Rochat TJ, Richter LM, Doll HA et al. Depression among pregnant rural South African women undergoing HIV testing. JAMA 2006; 295: 1376-1378.

  168. Sherr L, Fox Z, Lipton M, Whyte P, Jones P, Harrison U. Sustaining HIV testing in pregnancy - evaluation of routine offer of HIV testing in three London hospitals over 2 years. AIDS Care 2006; 18: 183-188.

  169. Kirshenbaum SB, Hirky AE, Correale J et al. 'Throwing the dice': pregnancy decision-making among HIV-positive women in four US cities. Perspect Sex Reprod Health 2004; 36: 106-113.

  170. Chen JL, Philips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 2001; 33: 144-152,165.

  171. Paiva V, Filipe EV, Santos N, Lima TN, Segurado A. The right to love: the desire for parenthood among men living with HIV. Reprod Health Matters 2003; 11: 91-100.

  172. UNAIDS/WHO. Antiretroviral Therapy and Sexual Transmission of HIV, Geneva: UNAIDS/WHO, 2008. Available online:

  173. Tovanabutra S, Robison V, Wongtrakul J et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29: 275-283.

  174. Garcia PM, Kalish LA, Pitt J et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341: 394-402.

  175. Rousseau CM, Nduati RW, Richardson BA et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187: 741-747.

  176. Lalani T, Hicks C. Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr HIV/AIDS Rep 2007; 4: 80-85.

  177. Cohn MA, Frankel SS, Rugpao S et al. Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J Infect Dis 2001; 184: 410-417.

  178. Grobman WA, Garcia PM. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol 1999; 181: 1062-1071.

  179. Chakraborty H, Sen PK, Helms RW et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15: 621-627.

  180. Gonzales MJ, Delwart E, Rhee SY et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis 2003; 188: 397-405.

  181. Tsui R, Herring BL, Barbour JD et al. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 2004; 78: 94-103.

  182. Smith DM, Wong JK, Hightower GK et al. HIV drug resistance acquired through superinfection. AIDS 2005; 19: 1251-1256.

  183. Parsons JT, Schrimshaw EW, Wolitski RJ et al. Sexual harm reduction practices of HIV-seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before ejaculation. AIDS 2005; 19 (Suppl.): 13-25.

  184. Fultz PN, Srinivasan A, Greene CR et al. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol 1987; 61: 4026-4029.

  185. Otten RA, Ellenberger DL, Adams DR et al. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis 1999; 180: 673-684.

  186. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192: 438-444.

  187. Pernas M, Casado C, Fuentes R, Perez-Elias MJ, Lopez-Galindez C. A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. J Acquir Immune Defic Syndr 2006; 42: 12-18.

  188. Blick G, Kagan RM, Coakley E et al. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 2007; 195: 1250-1259.

  189. Gottlieb GS, Nickle DC, Jensen MA et al. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363: 619-622.

  190. Grant RM, McConnell JJ, Herring BL et al. No superinfection among seroconcordant couples after well-defined exposure. 15th International AIDS Conference. Bangkok, Thailand, July 2003 [Abstract ThPeA6949].

  191. Vernazza PL, Hollander L, Semprini AE, Anderson DJ, Duerr A. HIV-discordant couples and parenthood: how are we dealing with the risk of transmission? AIDS 2006; 20: 635-636.

  192. Trussell J. Contraceptive efficacy. In: Hatcher R, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, eds. Contraceptive Technology, 19th revised edn. New York, NY: Ardent Media, 2004.

  193. Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. Fam Plan Perspect 1999; 31: 81-87.

  194. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002, Art. No. CD003255. DOI: [DOI link].

  195. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82: 454-461.

  196. National Institute of Allergy and Infectious Diseases. Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. Herndon, VA: National Institute of Allergy and Infectious Diseases, 2000. Available online: (last accessed 7 June 2008).

  197. French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female vs. male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003; 30: 433-439.

  198. Faculty of Family Planning and Reproductive Healthcare Clinical Effectiveness Unit. Guidance (January 2007) Male and Female Condoms. London: FFPRHC, 2007.

  199. No added STD protection from spermicidal condoms. Contracept Technol Update 1998; 19: 105-106.

  200. WHO/CONRAD technical consultation on nonoxynol-9, World Health Organization, Geneva, 9-10 October 2001: summary report. Reprod Health Matters 2002; 10: 175-181.

  201. Dawe F, Meltzer H. Contraception and Sexual Health, 2002: A Report on Research Using the ONS Omnibus Survey Produced by the Social Survey Division of the Office for National Statistics on Behalf of the Department of Health. London: Office for National Statistics, 2003.

  202. Wang CC, Reilly M, Kreiss JK. Risk of HIV infection in oral contraceptive pill users: a meta-analysis. J Acquir Immune Defic Syndr 1999; 21: 51-58.

  203. Morrison CS, Richardson BA, Mmiro F et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21: 85-95.

  204. Ouellet D, Hsu A, Qian J et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111-116.

  205. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Drug interactions with hormonal contraception, FFPRHC Guidance (April 2005). J Fam Plann Reprod Health Care 2005; 31: 139-151.

  206. Back DJ, Breckenridge AM, Crawford F et al. The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol 1979; 15: 193-197.

  207. Back DJ, Breckenridge AM, Crawford FE et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980; 21: 135-143.

  208. Gbolade BA. Depo-Provera and bone density. J Fam Plan Reprod Health Care 2002; 28: 7-11.

  209. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Faculty Statement from the Clinical Effectiveness Unit on Levonelle ® 1500 and the Use of Liver Enzyme Inducing Drugs. London: FFPRHC, 2006.

  210. Ahmed S, Lutalo T, Wawer M et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS 2001; 15: 2171-2179.

  211. Herbst JH, Sherba RT, Crepaz N et al. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. J Acquir Immune Defic Syndr 2005; 39: 228-241.

  212. Voeller B, Coulson AH, Bernstein GS, Nakamura RM. Mineral oil lubricants cause rapid deterioration of latex condoms. Contraception 1989; 39: 95-102.

  213. Gallo MF, Grimes DA, Schulz KF. Non-latex vs. latex male condoms for contraception. Cochrane Database Syst Rev 2003, Art. No. CD003550. DOI: 10.1002/14651858. CD003550.

  214. Golombok S, Harding R, Sheldon J. An evaluation of a thicker vs. a standard condom with gay men. AIDS 2001; 15: 245-250.

  215. Crittenden JA, Handelsman DJ, Stewart GJ. Semen analysis in human immunodeficiency virus infection. Fertil Steril 1992; 57: 1294-1299.

  216. Garrido N, Meseguer M, Remohi J, Simon C, Pellicer A. Semen characteristics in human immunodeficiency virus (HIV)- and hepatitis C (HCV)-seropositive males: predictors of the success of viral removal after sperm washing. Hum Reprod 2005; 20: 1028-1034.

  217. Politch JA, Mayer KH, Abbott AF, Anderson DJ. The effects of disease progression and zidovudine therapy on semen quality in human immunodeficiency virus type 1 seropositive men. Fertil Steril 1994; 61: 922-928.

  218. van Leeuwen E, Cornelissen M, de Vries JW et al. Semen parameters of a semen donor before and after infection with human immunodeficiency virus type 1: case report. Hum Reprod 2004; 19: 2845-2848.

  219. Robbins WA, Witt KL, Haseman JK et al. Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. J Infect Dis 2001; 184: 127-135.

  220. National Collaborating Centre for Women's and Children's Health (Commissioned by NICE). Fertility: Assessment and Treatment for People with Fertility Problems. London: Royal College of Obstetricians and Gynaecologists, 2004.

  221. Dulioust E, Du AL, Costagliola D et al. Semen alterations in HIV-1 infected men. Hum Reprod 2002; 17: 2112-2118.

  222. Lampe FC, Gatell JM, Staszewski S et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166: 521-528.

  223. Rotheram-Borus MJ, Lester P, Wang PW, Shen Q. Custody plans among patients living with human immunodeficiency virus infection. Arch Pediatr Adolesc Med 2004; 158: 327-332.

  224. Anderson J, Chalmers J, Nelson M et al. HIV transmission, the law, and the work of the clinical team. A briefing paper. London: British HIV Association, 2006. Available online: (last accessed 11 September 2006).

  225. Liverpool HIV Pharmacology Group. Effects of antiretroviral drugs on hormonal contraception. London: Department of Pharmacology and Therapeutics, 1999.

CLICK HERE for subscription information about this journal.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.